Pioglitazone promotes the proliferation of rat bone marrow endothelial progenitor cells

doi:10.3969/j.issn.2095-4344.2013.10.019

Abstract

Abstract:

BACKGROUND: Endothelial progenitor cells are characterized by proliferation, migration and the ability to differentiate into endothelial cells and play an important role in the occurrence and development of coronary arteriosclerotic heart disease and diabetes mellitus and their complications.
OBJECTIVE: To investigate the effects of selective peroxisome proliferative activated receptor γ excitomotor pioglitazone on the proliferation of rat bone marrow endothelial progenitor cells and the underlying mechanisms.
METHODS: Using density gradient centrifugation and differential adherence methods, rat bone marrow endothelial progenitor cells were cultured in culture medium containing 0, 1, 10, 50, 100, 200 μmol/L pioglitazone and the optimal concentration of pioglitazone in promoting the proliferation of endothelial progenitor cells was determined. The endothelial progenitor cells cultured for 7 days were randomly divided into five groups: control group (dimethyl sulfoxide), pioglitazone group (50 μmol/L pioglitazone), peroxisome proliferative activated receptor γ antagon group (50 μmol/L pioglitazone+10 μmol/L peroxisome proliferative activated receptor γ antagon GW9662), phosphatidylinositol 3-kinase/Akt blocker group (50 μmol/L pioglitazone+50 μmol/L phosphatidylinositol 3-kinase/protein kinase B channel blocker Wortmannin), extracellular regulated protein kinase blocker group (50 μmol/L pioglitazone+20 μmol/L extracellular regulated protein kinase blocker PD98059). The proliferation of endothelial progenitor cells in each group was observed.
RESULTS AND CONCLUSION: Through the inverted microscopy, cell proliferation was not obvious in the first 4 days of culture, peaked during 5-10 days, showing colony-forming units and line-like structure, and reached 80% confluency at 10 days. After 7 days of culture, endothelial progenitor cells could swallow DiL-ac-LDL and FITC-europaeus agglutinin-1. 10-200 μmol/L, particularly 50 μmol/L, pioglitazone could significantly promote the proliferation of endothelial progenitor cells (P < 0.01). Wortmannin and GW9662 could greatly antagonize pioglitazone promotion of cell proliferation, while PD98059 had no effects on the effects of pioglitazone. These findings suggest that pioglitazone promotes the proliferation of rat bone marrow endothelial progenitor cells via phosphatidylinositol 3-kinase/protein kinase B signaling pathway.

Key words: stem cells, stem cell culture and differentiation, endothelial progenitor cells, pioglitazone, proliferation, peroxisome proliferative activated receptor γ, signaling pathway, endothelial cells, angiogenesis, stem cell photograohs-containing paper

CLC Number:

R394.2

Zhang Hui-feng, Wang Li, Ma Yue-hua, Hu Zi-ying, Zhao Zhi-gang. Pioglitazone promotes the proliferation of rat bone marrow endothelial progenitor cells[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(10): 1827-1834.

Figures/Tables 9

References

[1] Ferguson JE 3rd, Kelley RW, Patterson C. Mechanisms of endothelial differentiation in embryonic vasculogenesis. Arterioscler Thromb Vasc Biol. 2005;25(11):2246-2254.

[2] Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-967.

[3] Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600.

[4] Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45(9):1449-1457.

[5] Fadini GP, Sartore S, Agostini C, et al. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007;30(5):1305-1313.

[6] Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26(9): 2140-2146.

[7] Ikeda U, Shimpo M, Murakami Y, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 2000;35(6):1232-1236.

[8] Guo YF, Zhao Y, Song DL, et al. Yixue Jianyan yu Linchuang. 2007;18(2):15-18. 郭永芳,赵莹,宋达琳,等.冠心病合并代谢综合征危险因素患者胰岛素抵抗与氧化应激的关系[J].医学检验与临床,2007,18(2): 15-18.

[9] Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3): 391-397.

[10] Cesari F, Gori AM, Romagnuolo I, et al. Endothelial progenitor cells and vascular health: effects of lifestyle's modifications. Monaldi Arch Chest Dis. 2012;78(2):66-72.

[11] Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105(25): 3017-3024.

[12] Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9(11):1370-1376.

[13] Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003;107 (24): 3059-3065.

[14] Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003;93(2):e17-24.

[15] Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364 (9429):141-148.

[16] Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-776.

[17] Tobler K, Freudenthaler A, Baumgartner-Parzer SM, et al. Reduction of both number and proliferative activity of human endothelial progenitor cells in obesity. Int J Obes (Lond). 2010;34(4):687-700.

[18] Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137(1):354-366.

[19] Lowell BB. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 1999; 99(3):239-242.

[20] Wang CH, Ciliberti N, Li SH, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109(11):1392-1400.

[21] Onuta G, Rienstra H, de Boer JF, et al. Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats. Transplantation. 2007;84(4):517-526.

[22] Bolten CW, Payne MA, McDonald WG, et al. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. Diab Vasc Dis Res. 2007;4(2):117-123.

[23] Gensch C, Clever YP, Werner C, et al. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007; 192(1):67-74.

[24] Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17: 615-675.

[25] Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85(3):221-228.

[26] Han JK, Kim HL, Jeon KH, et al. Peroxisome proliferator-activated receptor-{delta} activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine networks. Eur Heart J. 2011.

[27] Wang CH, Verma S, Hsieh IC, et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol. 2006;41(1):34-43.

[28] You D, Cochain C, Loinard C, et al. Combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;325(3):766-773.

[29] Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109(17):2058-2067.

[30] Thum T, Fraccarollo D, Galuppo P, et al. Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res. 2006;70(1): 50-60.

[31] Müller P, Kazakov A, Jagoda P, et al. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009;83(1):106-114.

[32] Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005;23(1):97-104.

[33] Yu Y, Fukuda N, Yao EH, et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens. 2008;21(1):72-77.

[34] Yao EH, Fukuda N, Matsumoto T, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res. 2007; 30(11):1119-1128.

[35] Pelliccia F, Pasceri V, Cianfrocca C, et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis. 2010;210(2): 510-515.

[36] Honda A, Matsuura K, Fukushima N, et al. Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. Atherosclerosis. 2009;205(2):376-384.

[37] Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43(5):993-1002.

[38] Steinmetz M, Brouwers C, Nickenig G, et al. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. J Cell Mol Med. 2010;14(6B):1645-1656.

[39] Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005; 45(4):526-529.